EXPAREL Expected to be Commercially Available in April 2012
Business WirePress Release: Pacira Pharmaceuticals, Inc. – Mon, Jan 9, 2012 6:30 AM EST
PARSIPPANY, N.J.--(BUSINESS WIRE)-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX - News) today provided updated timing for its commercial launch of EXPAREL® (bupivacaine liposome injectable suspension), a non-opioid analgesic that was approved by the U.S. Food and Drug Administration (FDA) for administration into the surgical site to produce postsurgical analgesia.
Since FDA approval of EXPAREL in October 2011, Pacira has continued to execute its pre-commercial launch strategy focused on the broad hospital market and has undertaken initiatives to expand and enhance its ability to efficiently manufacture commercial quantities of EXPAREL.
As planned, Pacira has hired and trained a sales force and will proceed with a formulary-access driven launch strategy, beginning with a national sales meeting this week. Due to commercial manufacturing challenges, which Pacira is confident it can address, the company projects product availability in April 2012, by which time Pacira expects it will have manufactured sufficient product to meet customer demands at launch.
“Our goal is to ensure that we have an appropriate commercial supply of EXPAREL to support anticipated demand for the product following our launch,” said Dave Stack, president and chief executive officer of Pacira. “We are encouraged by the positive response we have received following FDA approval of EXPAREL and our organization is focused on our commercial manufacturing processes. With the recent appointment of John Pratt to the newly created role of general manager for our San Diego manufacturing facility, we believe we have added leadership who will directly contribute to our ability to meet our goals. John has more than 35 years of experience in building and leading state-of-the art pharmaceutical manufacturing and quality control organizations including senior positions at Amylin and Novo Nordisk, and his expertise will be valuable as we execute our manufacturing strategy. We are very excited about EXPAREL and the role it can play in optimizing postsurgical pain management and look forward to bringing this product to the market.”
Taunia Markvicka, vice president, commercial at Pacira, added, “During the first quarter our sales force will work closely with our commercial and scientific affairs teams to achieve formulary approvals at our target hospitals. In line with our announced strategy, we have introduced multiple important educational initiatives, including preceptorship programs, and continued to work to implement opioid sparing protocols within several key institutions. We are also initiating our Phase 4 clinical programs that will provide healthcare professionals with hands-on experiences with the product. We believe all of these activities will help drive additional demand for EXPAREL as we continue to focus our promotional programs and investments to align the deployment of our resources with near-term revenue opportunities.”
Recent PCRX News
- Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029 • GlobeNewswire Inc. • 05/10/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:13:45 PM
- Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes • GlobeNewswire Inc. • 05/08/2024 08:05:14 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 08:02:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 08:01:03 PM
- Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program • GlobeNewswire Inc. • 05/07/2024 08:00:00 PM
- Pacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference • GlobeNewswire Inc. • 05/07/2024 12:00:00 PM
- Pacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024 • GlobeNewswire Inc. • 04/30/2024 12:00:00 PM
- Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/02/2024 12:00:00 PM
- Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee • GlobeNewswire Inc. • 03/13/2024 11:00:00 AM
- Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference • GlobeNewswire Inc. • 03/06/2024 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 08:33:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 01:03:32 PM
- Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results • GlobeNewswire Inc. • 02/29/2024 01:00:00 PM
- Pacira to Report 2023 Financial Results on Thursday February 29, 2024 • GlobeNewswire Inc. • 02/22/2024 01:00:00 PM
- Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy • GlobeNewswire Inc. • 02/15/2024 01:36:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 09:59:39 PM
- Pacira BioSciences Awarded Brand Pharmaceuticals Agreement With Premier, Inc. • GlobeNewswire Inc. • 02/07/2024 01:00:00 PM
- G.O.A.T. Bowl I Registration Open to 4 Additional Pickleball Teams • PR Newswire (US) • 02/01/2024 03:45:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 10:25:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 10:24:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 10:21:34 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 10:18:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 10:02:42 PM
- Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 Revenues • GlobeNewswire Inc. • 01/04/2024 10:00:41 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM